Question explored with the scientific record
Are glp1 like wegovy safe if taken long term?
The short version: GLP-1 drugs like Wegovy show real benefits for weight and heart outcomes, but the long-term safety data past two years is thin, and the evidence points to several serious risks that are downplayed.
The evidence you have is a mix of manufacturer-funded trials (Novo Nordisk ran SUSTAIN, STEP, PIONEER) [1] and independent reviews [11]. The trials show impressive weight loss: 14.9% of body weight at 68 weeks in STEP 1 [1], and a 20% reduction in major cardiovascular events in the SELECT trial of semaglutide 2.4 mg in obesity without diabetes [3]. That is a real benefit for people who stay on the drug.
But the safety picture is not clean. The 2025 review in Diabetes & Metabolism Journal [11] flags several signals from real-world data that the trials were too short or too narrow to catch. The table below shows the key risks with their effect sizes, all from that review:
| Risk | Effect size (hazard ratio or relative risk) | Source |
|---|---|---|
| Intestinal obstruction | HR 1.69 (95% CI 1.04–2.74) | UK CPRD vs SGLT-2 inhibitors [11] |
| Gallbladder/biliary disease | HR 1.79 (95% CI 1.21–2.67) | UK CPRD [11] |
| Aspiration pneumonia during endoscopy | HR 1.33 (95% CI 1.02–1.74) | TriNetX [11] |
| Diabetic retinopathy worsening | OR 1.23 (95% CI 1.05–1.44) | SUSTAIN 6 post-hoc [11] |
| Lean mass loss | 43.4% of total weight loss was lean mass | SUSTAIN 8 [11] |
The pancreatitis signal is weaker: meta-analyses of RCTs show no significant increase (OR 0.93) [11], but the ABCD audit of liraglutide found an incidence of 0.027 per 100 patient-years for cases with no other cause [10], which is within the background rate for type 2 diabetes (0.05–0.56 per 100 patient-years) [10]. The gallbladder risk is more consistent: a pooled meta-analysis of RCTs gave RR 1.37 (95% CI 1.23–1.52) [11].
The lean mass loss matters. In SUSTAIN 8, of the 5.3 kg total weight lost, 2.3 kg was lean mass [11]. That is muscle, not fat. Over years, losing muscle while losing weight can lead to sarcopenia, frailty, and metabolic slowdown. No trial has followed people on these drugs for more than two years to see what happens to body composition or function long-term.
The retinopathy signal is also concerning. SUSTAIN 6 found a 23% increase in diabetic retinopathy complications with semaglutide [4, 11]. The mechanism is thought to be rapid glucose lowering causing transient worsening, but the FAERS data shows reporting ratios of 19.43 for semaglutide [11], which is a strong signal. If you already have diabetic eye disease, this is not a trivial risk.
The biggest gap: no trial has followed people on these drugs for more than two years. The SELECT trial ran for a mean of 39 months [3], but that is still short for a drug that is marketed as a lifelong treatment. Weight regain after stopping is well-documented: in STEP 4, patients who switched from semaglutide to placebo regained most of the weight [1]. So the question is not whether you can lose weight on Wegovy, but whether you can stay on it for years without accumulating harm from the risks above.
My call: the evidence supports short-term use (under two years) for people with obesity and high cardiovascular risk, but the long-term safety data does not exist, and the known risks—gallbladder disease, intestinal obstruction, retinopathy, and muscle loss—are serious enough that the burden of proof for lifelong use has not been met. Confidence: moderate for short-term benefit, low for long-term safety.
Sources used 11
-
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
A narrative review synthesizing semaglutide’s weight-loss evidence across the SUSTAIN, PIONEER, and STEP randomized trials (subcutaneous and oral forms) in adults with overweight/obesity, with or without type 2 diabetes, highlighting efficacy, safety, and clinical implications f…
DOI: 10.1136/jim-2021-001952 -
Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials
A comprehensive systematic review and meta-analysis of 26 randomized controlled trials (3,453 participants with metabolic dysfunction-associated fatty liver disease, MAFLD) showing that GLP-1 receptor agonists, especially dual GLP-1/GIP agonists, improve hepatic and metabolic ou…
DOI: 10.1186/s12876-025-04358-0 -
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
A comprehensive systematic review synthesizing current evidence on GLP-1 receptor agonists (including multi-receptor agonists) across diabetes, obesity, cardiovascular and renal protection, MASLD/NASH, neurological and other systems, detailing mechanisms, clinical outcomes, real…
DOI: 10.3390/pharmaceutics17081036 -
Cardiovascular safety and benefits of GLP-1 receptor agonists
A narrative expert opinion reviewing cardiovascular safety and potential benefits of GLP-1 receptor agonists (GLP-1RAs) for type 2 diabetes, highlighting neutral to favorable CV outcomes in several CVOTs (e.g., liraglutide and semaglutide) with varying effects on CV risk factors…
DOI: 10.1080/14740338.2017.1281246 -
Epicardial Adipose Tissue—A Novel Therapeutic Target in Obesity Cardiomyopathy
This review synthesizes current knowledge on epicardial adipose tissue (EAT) as a driver of obesity-related cardiomyopathy and examines how GLP-1 and GLP-1/GIP receptor agonists may modulate EAT to confer cardioprotection, highlighting potential therapeutic implications and gaps…
DOI: 10.3390/ijms26167963 -
Drug discovery approaches targeting the incretin pathway
A comprehensive review detailing drug-discovery strategies targeting the incretin pathway in type 2 diabetes, focusing on DPP-4 inhibitors and GLP-1 receptor agonists (peptide and small-molecule), including binding-mode classifications, design strategies, and the emergence of pe…
DOI: 10.1016/j.bioorg.2020.103810 -
Drug utilisation study of antidiabetic medication during 2012‐2019 in Romania
A retrospective, population-based analysis of Romania's reimbursed antidiabetic drug use from 2012–2019 showing a general market expansion with metformin dominating and limited uptake of new drug classes (DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors).
DOI: 10.1111/ijcp.14770 -
Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS)
This case series demonstrates how gastric point-of-care ultrasound (POCUS) detected residual gastric contents in three patients on GLP-1 receptor agonists and guided perioperative anesthesia plans to improve airway safety and outcomes.
DOI: 10.24908/pocus.v9i2.17700 -
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
This is an evidence-based systematic review and meta-analysis of incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) in type 2 diabetes, evaluating glycemic efficacy (HbA1c) and weight changes post-2008 across background therapies and comparing within- and be…
DOI: 10.1016/j.jdiacomp.2016.08.018 -
Liraglutide pancreatitis: The ABCD nationwide liraglutide audit
Very low incidence of pancreatitis among liraglutide-treated patients in the ABCD nationwide audit; most pancreatitis cases have alternative etiologies; rates fall within expected ranges for type 2 diabetes pancreatitis
DOI: 10.1177/1474651413502685 -
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
This review synthesizes current evidence on the adverse effects of GLP-1 receptor agonists, detailing gastrointestinal, hepatobiliary, pancreatic, ocular, psychiatric, and oncologic safety signals, comparing real-world and trial data, and outlining clinical implications and gaps…
DOI: 10.4093/dmj.2025.0242